Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer
Cancers · 11.06.2024 · 16 (12) · 2189
DOI: 10.3390/cancers16122189 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 11.06.2024. Verfasst von Kennady K Bullock und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, Vanderbilt University, Nashville, TN 37232, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, BLRD VA, National Cancer Institute.
Abstract (Originalsprache)
The introduction of anti-programmed cell death protein-1 (anti-PD-1) to the clinical management of triple-negative breast cancer (TNBC) represents a breakthrough for a disease whose treatment has long relied on the standards of chemotherapy and surgery. Nevertheless, few TNBC patients achieve a durable remission in response to anti-PD-1, and there is a need to develop strategies to maximize the potential benefit of immune checkpoint inhibition (ICI) for TNBC patients. In the present review, we discuss three conceptual strategies to improve ICI response rates in TNBC patients. The first effort involves improving patient selection. We discuss proposed biomarkers of response and resistance to anti-PD-1, concluding that an optimal biomarker will likely be multifaceted. The second effort involves identifying existing targeted therapies or chemotherapies that may synergize with ICI. In particular, we describe recent efforts to use inhibitors of the PI3K/AKT or RAS/MAPK/ERK pathways in combination with ICI. Third, considering the possibility that targeting the PD-1 axis is not the most promising strategy for TNBC treatment, we describe ongoing efforts to identify novel immunotherapy strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, Vanderbilt University, Nashville, TN 37232, USA.
ORCID-Profile: Kennady K Bullock, Ann Richmond
Förderung
- NCI NIH HHS
- BLRD VA
- National Cancer Institute
Zitieren
APA
Bullock, K. K., & Richmond, A. (2024). Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer. Cancers, 16(12), 2189. https://doi.org/10.3390/cancers16122189
Vancouver
Bullock KK, Richmond A. Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer. Cancers. 2024;16(12):2189. doi:10.3390/cancers16122189
BibTeX
@article{Bullock2024,
author = {Bullock, Kennady K and Richmond, Ann},
title = {Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer},
journal = {Cancers},
year = {2024},
volume = {16},
number = {12},
pages = {2189},
doi = {10.3390/cancers16122189}
}
EUVIMED